Oral ibandronate has potent effects on the rate of bone resorption at doses which are generally well tolerated. Further development is appropriate to evaluate the effects of long-term administration in the prevention of metastatic bone disease and the management of established skeletal metastases.
The concern about the specificity of nucleic acid amplification tests (NAATs) in low prevalence GC populations is associated with its false positivity (cross-reactions with different Neisseria species) impacting on positive predictive value. Not all NAATs are the same and this type of false positivity has not been observed with AC2 to date. 2,3 In Cheshire and Merseyside, UK, we have since 2004 incorporated dual testing for chlamydia (CT) and GC into our chlamydia screening programmes using the Gen-Probe Aptima Combo 2 assay (AC2).Lavelle et al. in the Liverpool and South Sefton Chlamydia Screening Programme showed that, in those under age 25, a total of 55 cases of GC would have been missed if tested only for CT (47/4680(1%) of women and 8/473(1.7%) of men. Of the 47 women positive for GC, more than half, 26 (55%) were negative for CT. The CT prevalence in their population was 12% and 15.7% for women and men, respectively. 4 Our recent article in this journal showed that dual testing in the community contributed substantially to the overall number of GC cases found -40 community cases versus 35 at Macclesfield Genitourinary (GU) Medicine clinic. The overall prevalence of GC in the GU medicine clinic was 1.3% (true prevalence 0.9% on primary test) and that in the community was 0.4%. In the asymptomatic chlamydia screening population aged 15 -24 years, community tests made a total contribution of 32 cases (9/1330 [0.67%] men and 23/5070 [0.45%] women). 3 These 32 cases would have gone undiagnosed and untreated for GC within the community if the NAAT performed had been for CT alone. In our study too, the majority of the GC cases (.60%) were found in those with a negative result for CT. 5 Both of the above studies 4,5 thus show that dual testing at the outset would find more GC infections than reflex testing of CT positives.The Cheshire and Merseyside Sexual Health network already recommends concomitant screening for CT and GC using AC2 in asymptomatic low-risk individuals. 6 Publications from this region 5,7,8 have already shown that AC2 picks up extra cases of GC over and beyond culture in GU medicine clinics. The pick up of extra cases of GC at extragenital sites by AC2 has been reported by us and others. 5,9,10 Even in low prevalence populations we have demonstrated the opportunity to pick up substantial additional numbers of GC cases beyond those detected by current services. 11 The accumulating evidence shows that consideration of incorporating dual testing for CT and GC by the NCSP is long overdue and a wider consideration of application of GC NAATs should be considered.
The kidney allocation system (KAS) aims to improve deceased donor kidney transplant outcomes by matching of donor allografts and kidney recipients using the kidney donor risk index (KDRI) and recipient estimated post-transplant survival (EPTS) indices. In this single-center study, KAS was retroactively applied to 573 adult deceased donor kidney transplants (2004-2012) performed in the extended criteria/standard criteria donor (ECD/SCD) era. Donor KDRI and recipient EPTS were calculated, and transplants were analyzed to identify KAS fits. These were defined as allocation of top 20% allografts to top 20% recipients and bottom 80% allografts to bottom 80% recipients. On retroactive calculation, 70.2% of all transplants fit the KAS. Transplants that fit the KAS had inferior 1- and 5-yr patient survival (95.5% vs. 98.8%, p = 0.048, and 83.4% vs. 91.7%, p = 0.018) and similar 1- and 5-yr graft survival compared to transplants that did not fit the KAS (91.3% vs. 94.1%, p = 0.276, and 72.7% vs. 73.9%, p = 0.561). While EPTS correlated with recipient survival (HR = 2.96, p < 0.001), KDRI correlated with both recipient (HR = 3.56, p < 0.001) and graft survival (HR = 3.23, p < 0.001). Overall, retroactive application of the KAS to transplants performed in the ECD/SCD era did not identify superior patient survival for kidneys allocated in accordance with the KAS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.